Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703703 | 1.00 | KEAP1 (0.83) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| SCHEMBL8560109 | 1.00 | KEAP1 (0.83) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| SCHEMBL5988693 | 1.00 | KEAP1 (0.83) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| SCHEMBL5903339 | 1.00 | KEAP1 (0.83) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| SCHEMBL179978 | 0.98 | KEAP1 (0.86) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| SCHEMBL19922 | 0.91 | KEAP1 (1.00) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| SCHEMBL13878256 | 0.90 | KEAP1 (0.73) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| Hydrochloric Acid SCHEMBL11880824 | 0.88 | KEAP1 (0.95) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| Hydrochloric Acid SCHEMBL8934456 | 0.88 | KEAP1 (0.95) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| Ammonia Solution, Strong SCHEMBL1579906 | 0.88 | KEAP1 (0.95) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4670521-A | Process for producing tertiary amino group-containing vinyl polymers and curable resin compositions based on these polymers | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1987-06-02 | — | — | US | claimed |
| US-4634736-A | PAINTS | DAINIPPON INK & CHEMICALS (JP) | 1987-01-06 | — | — | US | claimed |
| WO-2023071601-A1 | DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 天津市昕晨投资发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| EP-2121771-B2 | NOVEL RADIATION CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2016-12-07 | — | — | EP | disclosed |
| US-8338499-B2 | Amine co-initiators for radiation curable compositions | AGFA GRAPHICS NV (BE) | 2012-12-25 | — | — | US | disclosed |
| EP-2121771-B1 | NOVEL RADIATION CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2012-06-27 | — | — | EP | disclosed |
| US-20100041784-A1 | NOVEL RADIATION CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2010-02-18 | — | — | US | disclosed |
| EP-2121771-A1 | NOVEL RADIATION CURABLE COMPOSITIONS | AGFA Graphics NV (BE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074758-A1 | NOVEL RADIATION CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2008-06-26 | — | — | WO | disclosed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| US-5424451-A | Used as cholinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1995-06-13 | — | — | US | disclosed |
| EP-0600092-A1 | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5302593-A | Aminoalkylcarbamic esters of eseroline suitable for use as chlorinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1994-04-12 | — | — | US | disclosed |
| EP-0575954-A1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-12-29 | — | — | EP | disclosed |
| EP-0156210-B1 | CURABLE RESIN COMPOSITIONS BASED ON TERTIARY AMINO GROUP-CONTAINING VINYL POLYMERS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1990-06-13 | — | — | EP | disclosed |
| US-4739083-A | REACTING 1,3-DIOXAN-4-ONE WITH (AMINE OR IMINE) SUBSTITUTED AMIDE | DAICEL CHEMICAL INDUSTRIES LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| US-4670521-A | Process for producing tertiary amino group-containing vinyl polymers and curable resin compositions based on these polymers | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1987-06-02 | — | — | US | disclosed |
| US-4634736-A | PAINTS | DAINIPPON INK & CHEMICALS (JP) | 1987-01-06 | — | — | US | disclosed |
| EP-0156210-A2 | Curable resin compositions based on tertiary amino group-containing vinyl polymers | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | KEAP1 1243/4885SMN1; SMN2 2242/4885HPGD 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.